https://scholars.lib.ntu.edu.tw/handle/123456789/635386
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Miklos, David Bernard | en_US |
dc.contributor.author | Abu Zaid, Mohammad | en_US |
dc.contributor.author | Cooney, Julian P | en_US |
dc.contributor.author | Albring, Jörn C | en_US |
dc.contributor.author | Flowers, Mary | en_US |
dc.contributor.author | Skarbnik, Alan P | en_US |
dc.contributor.author | Yakoub-Agha, Ibrahim | en_US |
dc.contributor.author | BOR-SHENG KO | en_US |
dc.contributor.author | Bruno, Benedetto | en_US |
dc.contributor.author | Waller, Edmund K | en_US |
dc.contributor.author | Yared, Jean | en_US |
dc.contributor.author | Sohn, Sang Kyun | en_US |
dc.contributor.author | Bulabois, Claude-Eric | en_US |
dc.contributor.author | Teshima, Takanori | en_US |
dc.contributor.author | Jacobsohn, David | en_US |
dc.contributor.author | Greinix, Hildegard | en_US |
dc.contributor.author | Mokatrin, Ahmad | en_US |
dc.contributor.author | Lee, Yihua | en_US |
dc.contributor.author | Wahlstrom, Justin T | en_US |
dc.contributor.author | Styles, Lori | en_US |
dc.contributor.author | Socie, Gerard | en_US |
dc.date.accessioned | 2023-09-14T08:55:35Z | - |
dc.date.available | 2023-09-14T08:55:35Z | - |
dc.date.issued | 2023-04-01 | - |
dc.identifier.issn | 0732183X | - |
dc.identifier.uri | https://pubmed.ncbi.nlm.nih.gov/36608310/ | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85151312872&doi=10.1200%2fJCO.22.00509&partnerID=40&md5=c981e5c7c8c6b3e9e6f3cc6715a76183 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/635386 | - |
dc.description.abstract | To present primary and final analyses from the randomized, double-blind, placebo-controlled, phase III iNTEGRATE study, which evaluated the safety and efficacy of ibrutinib with prednisone in previously untreated patients with chronic graft-versus-host disease (cGVHD). | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | en_US |
dc.title | Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1200/JCO.22.00509 | - |
dc.identifier.pmid | 36608310 | - |
dc.identifier.scopus | 2-s2.0-85151312872 | - |
dc.identifier.url | https://api.elsevier.com/content/abstract/scopus_id/85151312872 | - |
dc.relation.pages | 1876 | en_US |
dc.relation.journalvolume | 41 | en_US |
dc.relation.journalissue | 10 | en_US |
dc.relation.pageend | 1887 | en_US |
item.fulltext | no fulltext | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.grantfulltext | none | - |
item.openairetype | journal article | - |
item.languageiso639-1 | en | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.orcid | 0000-0002-7965-7579 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.